-
A
new oxazolidinone antibiotic
-
Excellent bioavailability when given orally.
-
Usual
adult dose: 600mg twelve hourly – oral or IV
-
Usual duration 10-14 days not advised for
treatment of longer that 28 days.
-
No
dosage reduction necessary if renal impairment.
-
A
reversible, non-selective inhibitor of monoamine oxidase. Has no
antidepressive activity at antibacterial doses.
-
Many precautions regarding it's use,
summarised below, for further information see manufacturer's
datasheet.
-
Patient
should be advised to avoid tyramine-rich foods.
-
Close
monitoring of blood pressure required if taking MAOIs, SSRIs, TCAs,
dopaminergics, pethidine, or if patient has uncontrolled hypertension,
thyrotoxicosis, bipolar depressive disorder or schizophrenia.
-
Check
full blood count weekly for all patients during therapy – myelosuppression possible.
-
Patients should be advised to report any
visual impairment such as changes in acuity, colour vision or field defects.
Patients who require >28 days therapy should have regular formal visual
assessments.
-
Patients should be advised to report any signs
of neuropathy, anaemia, thrombocytopenia or lactic acidosis.
